某院住院患者抗癫痫药物临床应用药物相关问题的调查分析

Investigation and Analysis on the Drug-related Problems in Clinical Application of Antiepileptic Drugs in Hospitalized Patients of One Hospital

目的:调查某院住院患者中抗癫痫药物使用情况,探讨抗癫痫药物临床应用药物相关问题(DRPs),为抗癫痫药物的临床合理应用提供参考。方法:对某院2016年使用抗癫痫药物的878份住院病历进行回顾性分析,统计患者的性别、年龄、病因,抗癫痫药物应用方案、使用情况、联合用药以及不良反应发生情况,同时采用国际通用的西班牙药物相关问题研究法(Granada-Ⅱ分类法)对抗癫痫药物的DRPs进行必要性、安全性、有效性研究。结果:878例中,男性患者居多(60.71%),50岁以上患者占比为69.02%,患者病因以脑血管疾病最多(323例,36.79%),共涉及7种抗癫痫药物,其中应用丙戊酸钠的病例数最多(489例,占51.75%);涉及DRPs具体问题分类有DRP2、DRP5、DRP6,分别为49例、22例及8例。结论:针对某院抗癫痫药物流行病学特点及临床应用DRPs具体问题,临床药师需加强对抗癫痫药物临床应用的DRPs的干预,促进临床安全合理用药。

Objective： To discuss the causes and characteristics of drug-related problems（ DRPs） of antiepileptic drugs by the investigation of antiepileptic drugs＇ use in our hospital in order to provide reference for the rational clinical application of antiepileptic drugs. Methods： A retrospective analysis on 878 inpatients＇ records including antiepileptic drug application in our hospital from January to December 2016 was carried out. The gender,age,etiology,application of antiepileptic drugs,usage,combination and adverse reactions were statistically analyzed in order to analyze the epidemiological characteristics of antiepileptic drugs in our hospital. At the same time,the necessity,safety and validity of the DRPs of antiepileptic drugs were studied by the international generic Spanish drug related research method（ Granada-Ⅱ classification method）. Results： Among the 878 cases,most were male patients（ 60. 71%） and the proportion of patients over 50 years old was 69. 02%. Patients with cerebrovascular diseases accounted for the most（ 323 cases,36. 79%）,and 7 varieties of antiepileptic drugs were involved,and sodium valproate was with the largest proportion（ 489 cases,51. 75%）. The DRPs were classified as DRP2（ 49 cases）,DRP5（ 22 cases） and DRP6（ 8 cases）. Conclusion： In view of the epidemiological characteristics of antiepileptic drugs and DRPs specific issues in clinical applications,clinical pharmacists need to strengthen the intervention in DRPs of antiepileptic drugs in order to promote the safety and reasonability of clinical application.